Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734 is registered in ClinicalTrials.gov with Alentis Therapeutics AG as lead sponsor.

NCT NCT07169734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Lead sponsor
Alentis Therapeutics AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 26, 2025
Completion date
October 4, 2029
Enrollment
180 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

cervical squamous cell carcinoma, colorectal cancer, intrahepatic cholangiocarcinoma, squamous non-small-cell lung cancer, urothelial carcinoma